Editing Novartis (section)

==Place in its market segments==
{{Update section|date=September 2018}}
Novartis is the world's first largest in life sciences and agribusiness markets.<ref name=":4" /> It is also the second-largest pharmaceutical company by market cap in 2019.<ref>{{Cite web |date=18 November 2019 |title=Top 10 Pharma Companies of 2019 |url=https://www.genengnews.com/a-lists/top-10-pharma-companies-of-2019/ |access-date=29 January 2021 |archive-date=11 November 2020 |archive-url=https://web.archive.org/web/20201111235919/https://www.genengnews.com/a-lists/top-10-pharma-companies-of-2019/ |url-status=live }}</ref> 
*Alcon: At the time Novartis bought Alcon, they had annual sales of $6.5&nbsp;billion and a net income of $2&nbsp;billion.<ref>{{Cite news |date=2010-12-15 |title=Novartis Snags Remaining 23% Stake in Alcon with $12.9B Cash and Share Deal {{!}} GEN - Genetic Engineering and Biotechnology News |language=en-US |work=GEN - Genetic Engineering and Biotechnology News |url=https://www.genengnews.com/news/novartis-snags-remaining-23-stake-in-alcon-with-12-9b-cash-and-share-deal/ |access-date=2020-01-14 |archive-date=13 August 2020 |archive-url=https://web.archive.org/web/20200813183415/https://www.genengnews.com/news/novartis-snags-remaining-23-stake-in-alcon-with-12-9b-cash-and-share-deal/ |url-status=live }}</ref> In April 2019, Novartis completed the spin-off of Alcon as a separate commercial entity.<ref name="auto">{{Cite web |title=Out From Under Novartis, Alcon Is Its Own Company Now |url=https://www.biospace.com/article/out-from-under-novartis-alcon-is-its-own-company-now/ |access-date=2019-04-10 |website=BioSpace |date=9 April 2019 |archive-date=23 September 2020 |archive-url=https://web.archive.org/web/20200923232425/https://www.biospace.com/article/out-from-under-novartis-alcon-is-its-own-company-now |url-status=live }}</ref>
*Sandoz: {{As of|2013}}, Sandoz has been recognized as the world's second-largest generic drug company. {{Citation needed|date=January 2020}} Sandoz' [[biosimilars]] lead its field, getting the first biosimilar approvals in the EU.<ref>Reuters, 21 October 2010 [http://uk.reuters.com/article/novartis-biosimilars-idUKLDE69K10V20101021?pageNumber=1 Biosimilars take off at Novartis generics unit] {{webarchive |url=https://web.archive.org/web/20131020160617/http://uk.reuters.com/article/2010/10/21/novartis-biosimilars-idUKLDE69K10V20101021?pageNumber=1 |date=20 October 2013 }}</ref><ref>Staff, Generics and Biosimilars Initiative, 9 November 2012 [http://www.gabionline.net/Biosimilars/Research/Sandoz-starts-phase-III-US-trial-for-biosimilar-epoetin-alfa Sandoz starts phase III US trial for biosimilar epoetin alfa] {{webarchive |url=https://web.archive.org/web/20131020092834/http://www.gabionline.net/Biosimilars/Research/Sandoz-starts-phase-III-US-trial-for-biosimilar-epoetin-alfa |date=20 October 2013 }}</ref> In 2018, Sandoz reported US$9.9&nbsp;billion in net sales.<ref>{{Cite web |title=20-F |url=https://www.sec.gov/Archives/edgar/data/1114448/000137036819000002/a19013020f.htm |access-date=2019-03-11 |website=www.sec.gov |page=63 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805133940/https://www.sec.gov/Archives/edgar/data/1114448/000137036819000002/a19013020f.htm |url-status=live }}</ref> In August 2022, Novartis announced plans to spin off Sandoz by second half of 2023.<ref name=sandoz-ft />
*Vaccines and Diagnostics Division: In 2013, Novartis announced it was considering selling the vaccines and diagnostics division off.<ref>{{Cite news |last=Morse |first=Andrew |date=2013-11-11 |title=Novartis Sells Unit for $1.68 Billion |language=en-US |work=Wall Street Journal |url=https://www.wsj.com/articles/novartis-sells-unit-for-168-billion-1384154246 |access-date=2020-01-21 |issn=0099-9660 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805082947/https://www.wsj.com/articles/novartis-sells-unit-for-168-billion-1384154246 |url-status=live }}</ref> This sale was completed in late 2015, and the division was integrated into [[CSL Limited|CSL]]'s BioCSL operation, with the combined entity trading as Seqirus.<ref>{{Cite web |title=CSL completes Novartis influenza vaccine acquisition in Germany |url=https://www.seqirus.com/newsroom/CSL-completes-Novartis-influenza-vaccine-acquisition-Germany |access-date=2019-01-09 |website=www.seqirus.com |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805174801/https://www.seqirus.com/newsroom/CSL-completes-Novartis-influenza-vaccine-acquisition-Germany |url-status=dead }}</ref><ref>{{Cite web |title=GSK Pharma completes acquisition of Novartis Healthcare's vaccines business |date=30 September 2015 |url=https://www.pharmaceutical-technology.com/news/newsgsk-pharma-completes-acquisition-of-novartis-healthcares-vaccines-business-4683437/ |access-date=2020-01-21 |language=en-GB |archive-date=5 January 2021 |archive-url=https://web.archive.org/web/20210105134713/https://www.pharmaceutical-technology.com/news/newsgsk-pharma-completes-acquisition-of-novartis-healthcares-vaccines-business-4683437/ |url-status=live }}</ref> In 2018, Novartis sold its consumer healthcare joint venture vaccines division to GlaxoSmithKline for US$13.0&nbsp;billion.<ref>{{Cite web |title=Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV |url=https://finance.yahoo.com/news/glaxo-gsk-buys-novartis-apos-131201109.html |access-date=2019-03-11 |website=finance.yahoo.com |date=28 March 2018 |archive-date=5 August 2020 |archive-url=https://web.archive.org/web/20200805171101/https://finance.yahoo.com/news/glaxo-gsk-buys-novartis-apos-131201109.html |url-status=live }}</ref>
*Consumer: Novartis is not a leader in the over-the-counter or animal health segments; its leading OTC brands are [[Excedrin]] and [[Theraflu]], but sales have been slowed by problems at its key US manufacturing plant.<ref>Staff and wire reports for the Journal Star (Lincoln, Nebraska) 14 August 2013 [http://journalstar.com/ap/business/novartis-reviews-business-analyst-urges-selling-otc-unit/article_535693f2-0a29-5cef-9804-f4100c174f41.html Novartis reviews business; analyst urges selling OTC unit] {{Webarchive|url=https://web.archive.org/web/20190424083534/https://journalstar.com/ap/business/novartis-reviews-business-analyst-urges-selling-otc-unit/article_535693f2-0a29-5cef-9804-f4100c174f41.html |date=24 April 2019 }}</ref>

In 2018, Novartis ranked second on the [[Access to Medicine Index]],<ref>Staff, WHO. [https://web.archive.org/web/20141203135449/http://apps.who.int/medicinedocs/documents/s19987en/s19987en.pdf Access to Medicine Index, 2012]</ref>{{rp|88}} which "ranks companies on how readily they make their products available to the world's poor."<ref>{{Cite web |title=Novartis AG |url=https://accesstomedicinefoundation.org/access-to-medicine-index/report-cards/novartis-ag |access-date=2019-11-22 |website=Access to Medicine Foundation |archive-date=30 January 2021 |archive-url=https://web.archive.org/web/20210130205024/https://accesstomedicinefoundation.org/access-to-medicine-index/report-cards/novartis-ag |url-status=live }}</ref><ref>{{Cite news |last=McNeil |first=Donald G. Jr. |date=2010-06-28 |title=The Drug Industry: GlaxoSmithKline, Merck and Novartis Again Rank Highest on Access to Poor |language=en-US |work=The New York Times |url=https://www.nytimes.com/2010/06/29/health/29glob.html |access-date=2020-01-21 |issn=0362-4331 |archive-date=10 September 2020 |archive-url=https://web.archive.org/web/20200910044539/https://www.nytimes.com/2010/06/29/health/29glob.html |url-status=live }}</ref>

=== Finance ===
As of January 31, 2025,  Novartis shares traded at over $104.72 per share, and its market capitalization was valued at $210.39B.<ref>{{Cite web |title=Novartis AG Market Cap 2010-2022 {{!}} NVS |url=https://www.macrotrends.net/stocks/charts/NVS/novartis-ag/market-cap |access-date=2023-02-01 |website=www.macrotrends.net |archive-date=1 February 2023 |archive-url=https://web.archive.org/web/20230201133230/https://www.macrotrends.net/stocks/charts/NVS/novartis-ag/market-cap |url-status=live }}</ref>
{| class="wikitable float-left" style="text-align: right;"
|-
!Year
!Revenue<br />in mil. US$
!Net income<br />in mil. US$
!Price per Share<br />in US$
!Employees
|-
|2005
|29,753
|6,130
|32.03
|
|-
|2006
|35,105
|7,175
|36.99
|
|-
|2007
|38,947
|11,946
|37.10
|
|-
|2008
|42,584
|8,195
|35.44
|
|-
|2009
|45,103
|8,400
|31.98
|
|-
|2010
|51,561
|9,794
|39.41
|
|-
|2011
|59,375
|8,940
|44.42
|
|-
|2012
|51,971
|9,270
|46.50
|
|-
|2013
|52,716
|9,175
|61.40
|135,696
|-
|2014
|53,634
|10,210
|76.50
|133,413
|-
|2015
|50,387
|17,783
|86.92
|122,966
|-
|2016
|49,436
|6,712
|71.10
|122,985
|-
|2017
|50,135
|7,703
|77.33
|126,457
|-
|2018
|46,099
|12,614
|91.13
|129,924
|-
|2019
|48,677
|11,732
|88.14
|103,914
|-
|2020
|49,898
|8,072
|84.38
|110,000
|-
|2021
|51,626
|24,018
|87.47
|110,000
|-
|2022
|50,545
|6,955
|80.56
|101,703
|-
|2023
|45,440
|14,854
|100.34
|76,057
|-
|2024
|50,317
|11,939
|104.72
|75,883
|}

=== Pricing ===

==== Entresto (sacubitril/valsartan) ====
In 2023, the Institute for Clinical and Economic Review (ICER) identified Entresto as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Entresto's wholesale acquisition cost rose by 7%, leading to an additional $72 million in costs to U.S. payers.<ref name="icer.org">{{Cite web |title=Institute for Clinical and Economic Review Announces Most Significant Drug-Price Hikes Unsupported by New Clinical Evidence in US |url=https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/?mkt_tok=NjM4LVBYUi0zMTgAAAGYMxe5Fv3mzhJbiVnr0V4g2FUAcS3PgZOZSYRvQcW3_VFPXIet0TCD7bWAyVVeW2Q62e3AynO8rDpP8sIoIbs_qux8kQcMBBD4cDSe3Q |access-date=2025-02-06 |website=ICER |language=en-US}}</ref>